R&D | May 25, 2026
Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
On-site medical room brings preventive care, routine consultations, and diagnostics closer to residents
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
